These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 18240145

  • 1. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME.
    Int J Cancer; 2008 May 15; 122(10):2368-76. PubMed ID: 18240145
    [Abstract] [Full Text] [Related]

  • 2. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
    Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI.
    Clin Cancer Res; 2008 Mar 01; 14(5):1510-8. PubMed ID: 18316576
    [Abstract] [Full Text] [Related]

  • 3. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM.
    Cancer Res; 2003 Apr 15; 63(8):1838-45. PubMed ID: 12702571
    [Abstract] [Full Text] [Related]

  • 4. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
    Choi ES, Shim JH, Jung JY, Kim HJ, Choi KH, Shin JA, Nam JS, Cho NP, Cho SD.
    Cancer Sci; 2011 Apr 15; 102(4):742-8. PubMed ID: 21241418
    [Abstract] [Full Text] [Related]

  • 5. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
    Neschadim A, Pritzker LB, Pritzker KP, Branch DR, Summerlee AJ, Trachtenberg J, Silvertown JD.
    Endocr Relat Cancer; 2014 Jun 15; 21(3):459-71. PubMed ID: 24812057
    [Abstract] [Full Text] [Related]

  • 6. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME.
    BJU Int; 2008 Aug 15; 102(3):389-97. PubMed ID: 18336596
    [Abstract] [Full Text] [Related]

  • 7. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G, Taylor SA, Marrinan CH, Hsieh Y, Bishop WR, Kirschmeier P, Long BJ.
    Int J Cancer; 2009 Dec 01; 125(11):2711-20. PubMed ID: 19530253
    [Abstract] [Full Text] [Related]

  • 8. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.
    Cancer Res; 2009 Oct 15; 69(20):8141-9. PubMed ID: 19808968
    [Abstract] [Full Text] [Related]

  • 9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
    Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046
    [Abstract] [Full Text] [Related]

  • 10. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G.
    J Cancer Res Clin Oncol; 2008 Jan 01; 134(1):51-7. PubMed ID: 17593391
    [Abstract] [Full Text] [Related]

  • 11. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S, Legrier ME, Boyé K, Bras-Gonçalves R, De Pinieux G, De Cremoux P, Poupon MF.
    J Urol; 2003 May 01; 169(5):1729-34. PubMed ID: 12686819
    [Abstract] [Full Text] [Related]

  • 12. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M.
    Int J Cancer; 2010 Jun 15; 126(12):2826-34. PubMed ID: 19876914
    [Abstract] [Full Text] [Related]

  • 13. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.
    Prostate; 2009 May 15; 69(7):744-54. PubMed ID: 19152342
    [Abstract] [Full Text] [Related]

  • 14. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X, Wu JB, Chung LW, Huang WC.
    Oncotarget; 2015 Dec 01; 6(38):41018-32. PubMed ID: 26512780
    [Abstract] [Full Text] [Related]

  • 15. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
    Torosyan Y, Simakova O, Naga S, Mezhevaya K, Leighton X, Diaz J, Huang W, Pollard H, Srivastava M.
    Int J Cancer; 2009 Dec 01; 125(11):2528-39. PubMed ID: 19610065
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS.
    Prostate; 2003 Jun 01; 55(4):299-307. PubMed ID: 12712409
    [Abstract] [Full Text] [Related]

  • 17. Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.
    Li X, Song Y, Zhang P, Zhu H, Chen L, Xiao Y, Xing Y.
    Tumour Biol; 2016 Jun 01; 37(6):7599-613. PubMed ID: 26687646
    [Abstract] [Full Text] [Related]

  • 18. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
    Day JM, Foster PA, Tutill HJ, Schmidlin F, Sharland CM, Hargrave JD, Vicker N, Potter BV, Reed MJ, Purohit A.
    Endocr Relat Cancer; 2013 Feb 01; 20(1):53-64. PubMed ID: 23132791
    [Abstract] [Full Text] [Related]

  • 19. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.
    Clin Cancer Res; 2005 Jul 01; 11(13):4905-11. PubMed ID: 16000589
    [Abstract] [Full Text] [Related]

  • 20. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.